文献速递胸部肿瘤

阿法替尼对比吉非替尼一线治疗晚期EGFR突变非小细胞肺癌的成本-效果分析

Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers.
PubMed 文献 · J Thorac Oncol · 2017-07-24

基于LUX-Lung 7试验的分区生存模型评估法国EGFR突变阳性NSCLC患者一线阿法替尼对比吉非替尼的成本-效果。全体人群ICER为每QALY 45211欧元(增量成本7697欧元,获得0.170 QALY),外显子19缺失和外显子21 L858R亚组ICER分别为38970和52518欧元。在70000欧元/QALY支付阈值下,阿法替尼具有成本-效果的概率为100%。

要点

  • 全体EGFR突变阳性NSCLC患者中,阿法替尼对比吉非替尼的ICER为每QALY 45211欧元。
  • 外显子19缺失亚组ICER为38970欧元/QALY,外显子21 L858R亚组为52518欧元/QALY。
  • 在70000欧元/QALY支付阈值下,阿法替尼具有成本-效果的概率为100%。

核心结论

  • 一线阿法替尼对比吉非替尼在EGFR突变阳性NSCLC患者中似乎具有成本-效果。

研究设计与样本

  • 采用分区生存模型,基于多中心、国际、随机、头对头2b期LUX-Lung 7试验,评估法国EGFR突变阳性NSCLC患者一线阿法替尼对比吉非替尼的成本-效果。
  • 结局和安全性主要来自LUX-Lung 7试验,资源使用和效用值来自该试验、专家小组问卷和已发表文献,支出限于直接成本。
  • 计算全体人群及EGFR外显子19缺失或外显子21 L858R突变亚组在10年时间 Horizon 的增量成本-效果比(ICER),并进行确定性和概率敏感性分析。

主要发现

  • 全体EGFR突变阳性NSCLC患者中,阿法替尼对比吉非替尼的ICER为每质量调整生命年(QALY)45211欧元(增量成本7697欧元,获得0.170 QALY)。
  • EGFR外显子19缺失和L858R亚组的ICER分别为38970欧元/QALY和52518欧元/QALY。
  • 在70000欧元/QALY的支付意愿阈值下,阿法替尼对常见EGFR突变患者具有成本-效果的概率为100%。

关键数值与推荐

  • 全体EGFR突变阳性NSCLC:ICER为45211欧元/QALY(增量成本7697欧元,QALY增益0.170)。
  • EGFR外显子19缺失亚组:ICER为38970欧元/QALY。
  • EGFR外显子21 L858R亚组:ICER为52518欧元/QALY。
  • 支付意愿阈值70000欧元/QALY时,阿法替尼具有成本-效果的概率为100%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: The irreversible ErbB family blocker afatinib and the reversible EGFR tyrosine kinase inhibitor gefitinib were compared in the multicenter, international, randomized, head-to-head phase 2b LUX-Lung 7 trial for first-line treatment of advanced EGFR mutation-positive NSCLCs. Afatinib and gefitinib costs and patients' outcomes in France were assessed. METHODS: A partitioned survival model was designed to assess the cost-effectiveness of afatinib versus gefitinib for EGFR mutation-positive NSCLCs. Outcomes and safety were taken primarily from the LUX-Lung 7 trial. Resource use and utilities were derived from that trial, an expert-panel questionnaire, and published literature, limiting expenditures to direct costs. Incremental cost-effectiveness ratios (ICERs) were calculated over a 10-year time horizon for the entire population, and EGFR exon 19 deletion or exon 21 L858R mutation (L858R) subgroups. Deterministic and probabilistic sensitivity analyses were conducted. RESULTS: For all EGFR mutation-positive NSCLCs, the afatinib-versus-gefitinib ICER of was €45,211 per quality-adjusted life-year (QALY) (0.170 QALY gain for an incremental cost of €7697). ICERs for EGFR exon 19 deletion and L858R populations were €38,970 and €52,518, respectively. Afatinib had 100% probability to be cost-effective at a willingness-to-pay threshold of €70,000/QALY for patients with common EGFR mutations. CONCLUSION: First-line afatinib appears cost-effective compared with gefitinib for patients with EGFR mutation-positive NSCLCs.

来源:J Thorac Oncol,查看原文。版权归原作者所有。

引用

  1. Chouaid C, Luciani L, LeLay K, et al. Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers. J Thorac Oncol. 2017. PMID: 28751244. doi:10.1016/j.jtho.2017.07.013

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。